Baltimore, Maryland 21231

  • Multiple Myeloma


The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.


Inclusion Criteria: - De novo multiple myeloma - ECOG 0-2 - No serious co-morbid illnesses and adequate organ function - > 4 weeks from systemic steroids Exclusion Criteria: - No existing secondary malignancies and no history of secondary malignancies in the past 5 years - No active autoimmune disease



Primary Contact:


Backup Contact:


Location Contact:

Baltimore, Maryland 21231
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.